Clinical trials: malaria
Uncomplicated Plasmodium Falciparum
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
Currently, the first-line combination of artemisinin, piperaquine and prima-quine is quite effective in controlling malaria, however, the threat of spread of drug-resistant parasites has been reported.
- Trial name
- MCHUPF (NCT05829187)
- Testing
- Dihydroartemisinin, Piperaquine, Primaquine
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
Malaria
The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention
The study is a cluster randomised trial to compare the effectiveness of indoor residual spraying (IRS) combined with the use of long lasting insecticidal nets (LLINs) with the effectiveness of LLINs alone for preventing malaria…
- Trial name
- NCT01697852
- Testing
- Indoor residual spraying with bendiocarb, LLIN by universal coverage campaign
- Where
- Tanzania
- Volunteers
- 22,300 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults
The study is designed to establish the best dose to safely infect healthy individuals with Plasmodium falciparum sporozoites (PfSPZ) by injection.
- Trial name
- NCT01771848
- Testing
- PfSPZ Challenge
- Where
- 2 sites in Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, Case Management
Proactive Community Case Management (Pro-CCM) in Rural Madagascar
The trial took place in a rural area hyper endemic for malaria, the hypothesis of which was that active detection and treatment of malaria in the population (all ages combined) in the event of a positive test could reduce the…
- Trial name
- Pro-CCM (NCT05223933)
- Testing
- Proactive community case management
- Where
- 22 sites in Madagascar
- Volunteers
- 1,000 people
- Sponsor
- Institut Pasteur de Madagascar
Malaria, Intermittent Preventive Treatment
Intermittent Preventive Treatment of Malaria in Schoolchildren
This will be a randomized, single-blinded, placebo-controlled trial to evaluate the efficacy, safety and tolerability of antimalarial regimens in healthy schoolchildren.
- Trial name
- NCT00852371
- Testing
- sulfadoxine-pyrimethamine, amodiaquine + sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine
- Volunteers
- 780 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period
A community-based, open-label, cluster-randomised longitudinal study in which children are randomized according to village health worker catchment areas comparing the safety and effectiveness of repeated treatments with…
- Trial name
- NCT01038063
- Testing
- Artemether-lumefantrine combination
- Where
- Malawi
- Volunteers
- 1,200 people
- Sponsor
- Liverpool School of Tropical Medicine
Pregnant Women
Malaria In Pregnancy in Central India
The present study is planned to be conducted at a district level women and children's hospital at Nagpur with the following objectives: Objectives: i) To assess the prevalence of asymptomatic malaria infection with all four…
- Trial name
- MIP (NCT03955263)
- Where
- India
- Volunteers
- 887 people, healthy volunteers welcome
- Sponsor
- Lata Medical Research Foundation, Nagpur
Malaria
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum
This study will evaluate the safety and effectiveness of a vaccine called AMA1-C1/ISA. Malaria is a serious infection of red blood cells caused by a parasite. There are 300 to 500 million malaria cases worldwide each year.
- Trial name
- NCT00487916
- Testing
- AMA1-C1/ISA 720
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs
The purpose of this study is to determine if adherence and effectiveness of AL in the treatment of uncomplicated malaria in children aged under five years using blister packs with pictorial leaflets can be at levels comparable to…
- Trial name
- NCT01065116
- Testing
- AL Blister-packs with Instruction leaflets, AL unit dose age specific pre-packs
- Where
- Uganda
- Volunteers
- 920 people
- Sponsor
- Malaria Consortium, Uganda
Malaria,Falciparum, Malaria
Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities
This community-based cluster randomized controlled trial aims to evaluate the effectiveness of time-limited, community-wide mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHA-PPQ) and single low-dose…
- Trial name
- NCT04864444
- Testing
- Dihydroartemisinin-piperaquine, Primaquine
- Where
- Senegal
- Volunteers
- 10,715 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Plasmodium and Other Parasites in Pregnant Women and Children Around Margibi and Montserrado Counties, Liberia
Background: The disease malaria affects many people in Liberia and other parts of Africa. It is caused by germs that are spread by mosquito bites.
- Trial name
- NCT03719599
- Where
- 2 sites in Liberia
- Volunteers
- 1,264 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire
The primary objective of this study is to demonstrate the non-inferiority of Polymerase Chain Reaction (PCR)-adjusted adequate clinical and parasitological response to artesunate plus amodiaquine at Day 28 in two groups of…
- Trial name
- NCT01023399
- Testing
- Artesunate + Amodiaquine
- Where
- Côte d’Ivoire
- Volunteers
- 580 people
- Sponsor
- Sanofi
Plasmodium Falciparum, Malaria
Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection
Plasmodium falciparum isolates display a wide genetic diversity with possibly different properties to induce immune responses. These properties could directly influence the ability to induce protective efficacy.
- Trial name
- TIP1 (NCT01002833)
- Testing
- Exposure to Plasmodium falciparum infected mosquitoes
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Healthy
Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine
Malaria is responsible for over 2 million deaths each year. The development of an efficient vaccine would present by far the best solution for solving this disastrous situation.
- Trial name
- LSA-3-rec (NCT00509158)
- Testing
- arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant, arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria Asymptomatic Parasitaemia
Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence in Ghana
Globally, malaria prevalence in 2016 was reported to have increased with 445,000 deaths, 91% of which occurred in sub-Sahara Africa with more than 75% being children.
- Trial name
- DetI-MTTT (NCT04301531)
- Testing
- Mass testing using RDTs, Treatment for all cases confirmed positive malaria cases with ACTs, Determination of Hb
- Where
- Ghana
- Volunteers
- 5,861 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research
Malaria
In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso
Resistance to antimalarial drugs represents a major obstacle for controlling malaria in endemic countries, so that most sub-Saharan countries have changed their antimalarial drug policy to the new Artemisinin Containing…
- Trial name
- NCT00808951
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- Burkina Faso
- Volunteers
- 440 people
- Sponsor
- Centre Muraz
Sepsis Newborn, Malaria
Immune Dysfunction in Newborn Sepsis
The aim of the project is to study neonatal immune dysfunction associated to the risk of newborn sepsis in a malaria endemic area in Benin.
- Conditions
- Sepsis Newborn, Malaria, Immune Responses
- Trial name
- RECIPAL (NCT03780712)
- Testing
- Non applicable
- Volunteers
- 585 people
- Sponsor
- BioMérieux
Malaria, Hiv
OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa
A longitudinal study with four parallel cohorts with each participant followed for 2 years: two cohorts in Busia (high malaria transmission site) and two cohorts in Kampala (low malaria transmission).
- Trial name
- OPTIMAH (NCT06967519)
- Testing
- Artemether-lumefantrine (AL), artesunate-amodiaquine (AS-AQ)
- Where
- 2 sites in Uganda
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Yale University
Plasmodium Falciparum Infection
rCSP/AP10-602 [GLA-LSQ] Vaccine Trial
This is a study to evaluate the safety, immunogenicity, and efficacy of a recombinant circumsporozoite protein (rCSP) malaria vaccine administered with and without AP 10-602 [Glucopyranosyl Lipid A (GLA) in liposome Quillaja…
- Trial name
- NCT03589794
- Testing
- AP10-602, Malaria challenge, rCSP
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
Background: The disease malaria affects many people in Mali and other parts of Africa and the world. It is caused by germs spread by mosquito bites. Malaria may be mild.
- Trial name
- NCT03510481
- Testing
- PfSPZ Vaccine, Normal Saline, artemether 20mg/lumefantrine 120mg (AL)
- Where
- Mali
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.